Elsevier

Drug and Alcohol Dependence

Volume 156, 1 November 2015, Pages 47-56
Drug and Alcohol Dependence

Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions – III

https://doi.org/10.1016/j.drugalcdep.2015.08.026Get rights and content

Highlights

  • We examine prevalence, correlates, comorbidity and treatment of NMPOU.

  • We examine DSM-5 NMPOUD among men and women.

  • Prevalences of 12-month and lifetime NMPOU were greater among men than women.

  • Rates of NMPOUD did not differ between men and women.

  • MDD, persistent depression and bipolar I disorder were associated with NMPOU and NMPOUD among men.

Abstract

Background

Little is known about sex-specific risk for nonmedical prescription opioid use (NMPOU) and DSM-5 nonmedical prescription opioid use disorder (NMPOUD). The objective of the present study was to present prevalence, correlates, psychiatric comorbidity, treatment and disability of NMPOU and DSM-5 NMPOUD among men and women.

Methods

Nationally representative sample of the U.S.

Results

Prevalences of 12-month and lifetime NMPOU were greater among men (4.4%, 13.0%) than women (3.9%, 9.8%), while corresponding rates of DSM-5 NMPOUD did not differ between men (0.9%, 2.2%) and women (0.9%, 1.9%). Regardless of time frame and sex, NMPOU and NMPOUD generally decreased with age and were lower among Blacks, Asians/Pacific Islanders and Hispanics, and respondents with lower socioeconomic status. Among men with NMPOU, rates were lower among respondents in the Northeast and South and among those previously married (lifetime). Across time frames and gender, NMPOU and NMPOUD were generally associated with other substance use disorders, posttraumatic stress and borderline, schizotypal and antisocial personality disorders, but associated with major depressive disorder, persistent depression and bipolar I disorder only among men. Disability increased with NMPOU frequency and NMPOUD severity. Only 7.6% and 8.2% of men and women with NMPOU ever received treatment, while 26.8% and 31.1% ever received treatment for NMPOUD.

Conclusions

NMPOU and NMPOUD are highly disabling, associated with a broad array of sex-specific and shared correlates and comorbidities and largely go untreated in the U.S. Valid assessment tools are needed that include gender as a stratification variable to identify NMPOU and NMPOUD.

Introduction

The past decade has witnessed a startling rise in harms from nonmedical prescription opioid use (NMPOU): drug poisoning death rates attributable to NMPOU have tripled; (Warner et al., 2012), opioid-related emergency room visits increased by 153%; (Substance Abuse and Mental Health Services Administration (SAMHSA), 2013) and drug treatment admission rates for nonheroin opioids increased 236% (SAMHSA, 2014). NMPOU is also associated with many other adverse health consequences including nonmedical prescription opioid use disorder (NMPOUD; Huang et al., 2006), psychiatric comorbidity (Amari et al., 2011, Becker et al., 2008, Compton et al., 2005, Katz et al., 2013, Martins et al., 2009, Martins et al., 2012), cognitive impairment and drug interactions (U.S Department of Health and Human Services, 2011), transitions to injection drug or heroin use with resultant infections (Jones, 2013, Pollini et al., 2011, Muhuri et al., 2013), falls and fractures among older adults (Miller et al., 2011, Rolita et al., 2013) and neonatal opioid withdrawal syndrome (Creanga et al., 2012). Societal costs of NMPOU and NMPOUD are estimated at $53–$72 billion annually (Birnbaum et al., 2011, Coalition Against Insurance Fraud, 2007, Hansen et al., 2011).

Despite important sex differences in sociodemographic and clinical correlates of NMPOU and NMPOUD observed among chronic pain patients (Campbell et al., 2010, Fillingim et al., 2003, Jamison et al., 2010, Manubay et al., 2015) and individuals in substance abuse treatment (Back et al., 2011, Green et al., 2009, McHugh et al., 2013), little is known about sex-specific correlates of NMPOU and NMPOUD in the U.S. general population. This is especially true for NMPOUD since few national surveys have collected the information necessary to derive diagnoses of NMPOUD and the full range of its psychiatric comorbidities. In the 2001–2002 National Institute on Alcohol Abuse and Alcoholism's (NIAAA) National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 12-month and lifetime rates of NMPOU were greater among men (2.1%; 6.1%) than women (1.5%; 3.5%; Huang et al., 2006). Similarly, 12-month and lifetime prevalences of Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV; American Psychiatric Association, 1994) NMPOUD were greater among men (0.5%; 2.0%) than women (0.2%; 0.9%). Substantial comorbidity was observed among NMPOUD and other DSM-IV substance, mood anxiety and personality disorders (Huang et al., 2006).

In the 2013 Substance Abuse and Mental Health Services Administration's National Survey on Drug Use and Health (NSDUH), prevalences of DSM-IV 12-month and lifetime NMPOU were greater among men (4.6% and 15.7%) than women (3.8% and 12.7%; SAMHSA, 2014). The rate of 12-month DSM-IV NMPOUD in 2013 was also greater among men (0.9%) than women (0.6%). Studies using earlier data from the NSDUH found greater rates of NMPOU among men (Back et al., 2010, Tetrault et al., 2007) but no sex differences in rates of 12-month NMPOUD (Back et al., 2010). However, NSDUH does not assess lifetime diagnoses, disability or the full range of psychiatric disorders.

To date, only one national survey has examined sex-specific risk profiles of NMPOU and NMPOUD directly, using data from 2003, which are now over a decade old (Tetrault et al., 2007). Moreover, all previous national estimates of NMPOUD were based on DSM-IV criteria. However, DSM-5 (American Psychiatric Association, 2013) made major changes to the NMPOUD diagnosis, including combining most abuse and dependence criteria into a single diagnosis, adding a craving criterion, and setting a diagnostic threshold of ≥2 criteria (Hasin et al., 2013). Major changes were also made to mood and anxiety disorders, suggesting the need to examine NMPOUD and its psychiatric correlates using DSM-5 criteria.

Because of the seriousness of NMPOU and NMPOUD, the lack of gender-specific information about NMPOU and DSM-5 NMPOUD in the United States from a single, reliable and uniform source represents a critical knowledge gap. We therefore present sex-specific national data on the prevalence, correlates, comorbidity, disability and treatment of NMPOU and DSM-5 NMPOUD from 2012 to 2013 NIAAA NESARC-III (Grant et al., 2014).

Section snippets

Sample

The target population of NESARC-III was the U.S. noninstitutionalized adult civilian population residing in households and selected group quarters. As detailed elsewhere (Grant et al., 2014), probability sampling was used to select respondents. Primary sampling units were counties or groups of contiguous counties, secondary sampling units (SSUs) comprised groups of Census-defined blocks, and tertiary sampling units were households within SSUs. Eligible adults within sampled households were

NMPOU

The prevalences of 12-month NMPOU were greater among men than women (4.4% and 3.9%; adjusted odds ratio (AOR) = 1.2, 95% confidence limit (CI) = 1.04–1.32) (Table 1). Among both sexes, rates of 12-month NMPOU were lower among Asian/Pacific Islanders and in the two youngest age groups and among those with incomes <$20,000.00. Among men, the prevalence of NMPOU was also lower among respondents with annual incomes between $35,000.00 and $69,999.00 and residents of the Northeast. Among women,

Discussion

In 2012–2013, prevalences of 12-month NMPOU were greater among men (4.4%) than women (3.9%), representing about 5.0 and 4.7 million adult Americans. Lifetime rates of NMPOU were also considerably greater among men (13.0%) than women (9.8%) or 26.7 and 14.7 million Americans. In contrast, 12-month (0.9%, 0.9%) and lifetime (2.2%, 1.9%) prevalences of NMPOUD did not differ by sex.

The sex difference observed in NMPOU is consistent with prior surveys (Back et al., 2010, Huang et al., 2006, SAMHSA,

Role of funding source

The NESARC-III was funded and sponsored by the National Institute on Alcohol Abuse and Alcoholism, with supplemented support from the National Institute on Drug Abuse. The sponsors had no involvement in the study design, collection, analysis and interpretation of the data, in the writing of the report and in the decision to submit the article for publication.

Contributors

Dr. Kerridge wrote the first draft of the manuscript and all other authors contributed to subsequent draft revisions. Drs. Kerridge, Saha, Zhang, Jung, Ruan and Smith contributed to the data analyses. All authors participated in the concept, design and collection of study data.

Conflict of interest

No authors claim conflict of interest.

Acknowledgements

This research was supported by the National Institute on Drug Abuse, National Institutes of Health (5F32DA0364431: Dr. Kerridge), the National Institute on Alcohol Abuse and Alcoholism (K05AA014223: Dr. Hasin), the New York State Psychiatric Institute (Dr. Hasin), and the in intramural program, NIAAA, NIH.

References (85)

  • T.C. Green et al.

    Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database

    Drug Alcohol Depend.

    (2009)
  • D.S. Hasin et al.

    The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance disorders modules through clinical re-appraisal in a general population sample

    Drug Alcohol Depend.

    (2015)
  • D.S. Hasin et al.

    Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: substance abusers and others in a general population sample

    Drug Alcohol Depend.

    (2015)
  • R.N. Jamison et al.

    Gender differences in risk factors for aberrant prescription opioid use

    J. Pain

    (2010)
  • M.K. Jensen et al.

    10-year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization

    Eur. J. Pain

    (2006)
  • C.M. Jones

    Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers – United States, 2002–2004 and 2008–2010

    Drug Alcohol Depend.

    (2013)
  • C. Katz et al.

    Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample

    Drug Alcohol Depend.

    (2013)
  • A.M. Kobus et al.

    Correlates of higher-dose opioid medication use for low back pain in primary care

    J. Pain

    (2012)
  • S.S. Martins et al.

    Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions

    Drug Alcohol Depend.

    (2009)
  • R.K. McHugh et al.

    Prescription drug abuse: from epidemiology to public policy

    J. Subst. Abuse Treat.

    (2015)
  • R.K. McHugh et al.

    Gender differences in a clinical trial for prescription opioid dependence

    J. Subst. Abuse Treat.

    (2013)
  • S.P. Novak et al.

    Physician pain, common psychiatric and substance use disorders; and the non-medical use of prescription analgesics in the United States

    Drug Alcohol Depend.

    (2009)
  • J. Parsells-Kelly et al.

    Prevalence and characteristics of opioid use in the US adult population

    Pain

    (2008)
  • J.J.J. Schuch et al.

    Gender differences in major depressive disorder: results from the Netherlands study of depression and anxiety

    J. Affect. Disord.

    (2014)
  • L. Simoni-Wastila et al.

    Psychoactive drug abuse in older adults

    Am. J. Geriatr. Pharmacother.

    (2006)
  • F.S. Stinson et al.

    Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions

    Drug Alcohol Depend.

    (2005)
  • M.D. Sullivan et al.

    Opioid therapy for chronic pain in the United States: promises and perils

    Pain

    (2013)
  • E. Thomas et al.

    The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the North Staffordshire Osteoarthritis Project

    Pain

    (2004)
  • K.H. Wang et al.

    Prevalence and correlates for nonmedical use and prescription opioids among urban and rural residents

    Drug Alcohol Depend.

    (2013)
  • C.M. Weisner et al.

    Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders

    Pain

    (2009)
  • N.A. West et al.

    Trends in abuse and misuse of prescription opioids among older adults

    Drug Alcohol Depend.

    (2015)
  • L.-T. Wu et al.

    Illicit and nonmedical drug use among Asian Americans, Native Hawaiians/Pacific Islanders, and mixed-race individuals

    Drug Alcohol Depend.

    (2013)
  • E. Amari et al.

    Nonmedical prescription opioid use and mental health and pain comorbidities: a narrative review

    Can. J. Psychiatry

    (2011)
  • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders

    (1994)
  • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders

    (2013)
  • S.E. Back et al.

    Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial

    Am. J. Drug Alcohol Abuse

    (2011)
  • H.G. Birnbaum et al.

    Societal costs of prescription opioid abuse, dependence and misuse in the United States

    Pain Med.

    (2011)
  • C.J. Boyd et al.

    Non-medical use of prescription analgesics: a three-year national longitudinal study

    J. Addict. Dis.

    (2009)
  • Bureau of the Census

    American Community Survey, 2012

    (2012)
  • C.I. Campbell et al.

    Age and gender trends in long-term opioid analgesic use for noncancer pain

    Am. J. Public Health

    (2010)
  • Centers for Disease Control and Prevention

    Unweighted Response Rates for the NHANES 2011–2012

    (2013)
  • Coalition Against Insurance Fraud

    Prescription for Peril: How Insurance Fraud Finances Theft and Abuse of Addictive Prescription Drugs

    (2007)
  • Cited by (0)

    View full text